艾伯维-话题@MedSci

#艾伯维#

43篇内容 | 2911人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1350216, encodeId=fe8413502168b, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维关节炎新药upadacitinib抵达3期终点效果优于Humira, objectType=article, longId=134758, objectId=7a56134e586f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a56134e586f, replyNumber=0, likeNumber=87, createdTime=2018-04-12, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a56134e586f, moduleTitle=艾伯维关节炎新药upadacitinib抵达3期终点效果优于Humira, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a56134e586f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350215, encodeId=5b73135021563, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维旗下维建乐®（奥比帕利片）联合易奇瑞®（达塞布韦钠片）治疗方案在华获批用于治疗基因1型慢性丙肝, objectType=article, longId=122564, objectId=3ffa12256425, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ffa12256425, replyNumber=0, likeNumber=81, createdTime=2017-12-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ffa12256425, moduleTitle=艾伯维旗下维建乐®（奥比帕利片）联合易奇瑞®（达塞布韦钠片）治疗方案在华获批用于治疗基因1型慢性丙肝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ffa12256425)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350214, encodeId=2cb613502147c, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维修订增强型拟肽类PIs口服联合制剂克力芝®（洛匹那韦/利托那韦）的说明书, objectType=article, longId=121164, objectId=247f1211642b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=247f1211642b, replyNumber=0, likeNumber=81, createdTime=2017-11-25, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=247f1211642b, moduleTitle=艾伯维修订增强型拟肽类PIs口服联合制剂克力芝®（洛匹那韦/利托那韦）的说明书, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=247f1211642b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350213, encodeId=36e8135021385, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维产品修美乐在华获批用于治疗中重度斑块型银屑病, objectType=article, longId=101021, objectId=091a10102187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=091a10102187, replyNumber=0, likeNumber=94, createdTime=2017-06-09, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=091a10102187, moduleTitle=艾伯维产品修美乐在华获批用于治疗中重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=091a10102187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350212, encodeId=3e6f1350212c4, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功, objectType=article, longId=87131, objectId=d5598e13167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5598e13167, replyNumber=0, likeNumber=88, createdTime=2017-01-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5598e13167, moduleTitle=艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5598e13167)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350211, encodeId=d56a13502119b, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=ASRM2016：女性福音！艾伯维妇科药物Elagolix治疗子宫内膜异位症显著减少经期和非经期盆腔疼痛, objectType=article, longId=80715, objectId=47f180e1502, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47f180e1502, replyNumber=0, likeNumber=121, createdTime=2016-10-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47f180e1502, moduleTitle=ASRM2016：女性福音！艾伯维妇科药物Elagolix治疗子宫内膜异位症显著减少经期和非经期盆腔疼痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47f180e1502)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350210, encodeId=8b671350210e8, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=ECTRIMS 2016：百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta疗效显著优于Avonex（干扰素β-1a）, objectType=article, longId=78356, objectId=ead2e8356ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ead2e8356ce, replyNumber=0, likeNumber=80, createdTime=2016-09-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ead2e8356ce, moduleTitle=ECTRIMS 2016：百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta疗效显著优于Avonex（干扰素β-1a）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ead2e8356ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350209, encodeId=968a1350209f3, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=喜讯！百健和艾伯维每月一次皮下注射多发性硬化症药物Zinbryta获欧盟批准, objectType=article, longId=72275, objectId=7697e227519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7697e227519, replyNumber=0, likeNumber=113, createdTime=2016-07-09, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7697e227519, moduleTitle=喜讯！百健和艾伯维每月一次皮下注射多发性硬化症药物Zinbryta获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7697e227519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350208, encodeId=0089135020825, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, objectType=article, longId=70030, objectId=0f9ae003001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f9ae003001, replyNumber=0, likeNumber=0, createdTime=2016-06-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f9ae003001, moduleTitle=第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f9ae003001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350207, encodeId=92e4135020e27, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=喜讯！FDA批准百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta, objectType=article, longId=69494, objectId=393e69494f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=393e69494f9, replyNumber=0, likeNumber=122, createdTime=2016-06-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=393e69494f9, moduleTitle=喜讯！FDA批准百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=393e69494f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350206, encodeId=1a0e13502064a, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维旗舰产品修美乐（Humira）获欧盟CHMP支持批准，治疗非感染性葡萄膜炎, objectType=article, longId=69400, objectId=f315694009f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f315694009f, replyNumber=0, likeNumber=103, createdTime=2016-05-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f315694009f, moduleTitle=艾伯维旗舰产品修美乐（Humira）获欧盟CHMP支持批准，治疗非感染性葡萄膜炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f315694009f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350205, encodeId=f91c13502059b, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=6个适应症！FDA批准艾伯维突破性药物Imbruvica治疗小淋巴细胞性淋巴瘤（SLL）, objectType=article, longId=67960, objectId=cc206e96084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc206e96084, replyNumber=0, likeNumber=137, createdTime=2016-05-12, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc206e96084, moduleTitle=6个适应症！FDA批准艾伯维突破性药物Imbruvica治疗小淋巴细胞性淋巴瘤（SLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc206e96084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350204, encodeId=9460135020405, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维/罗氏白血病新药 Venclexta再获FDA突破性药物资格, objectType=article, longId=66601, objectId=517566601fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=517566601fe, replyNumber=0, likeNumber=0, createdTime=2016-04-18, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=517566601fe, moduleTitle=艾伯维/罗氏白血病新药 Venclexta再获FDA突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=517566601fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350203, encodeId=d07013502033f, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=5个适应证！FDA批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, objectType=article, longId=64673, objectId=6448646e38c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6448646e38c, replyNumber=0, likeNumber=72, createdTime=2016-03-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6448646e38c, moduleTitle=5个适应证！FDA批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6448646e38c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350202, encodeId=8de013502025e, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=性福音！艾伯维妇科药物Elagolix治疗子宫内膜异位症III期项目大获成功, objectType=article, longId=63535, objectId=f1316353526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1316353526, replyNumber=0, likeNumber=83, createdTime=2016-02-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1316353526, moduleTitle=性福音！艾伯维妇科药物Elagolix治疗子宫内膜异位症III期项目大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1316353526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350201, encodeId=c8e713502015a, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维白血病新药venetoclax斩获FDA第2个突破性药物资格, objectType=article, longId=62538, objectId=ba72625386b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba72625386b, replyNumber=0, likeNumber=91, createdTime=2016-01-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba72625386b, moduleTitle=艾伯维白血病新药venetoclax斩获FDA第2个突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba72625386b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350200, encodeId=61c113502009b, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维丙肝鸡尾酒Viekira Pak治疗肝硬化1b型丙肝实现100%治愈率, objectType=article, longId=52528, objectId=b72b52528ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b72b52528ea, replyNumber=0, likeNumber=81, createdTime=2015-06-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b72b52528ea, moduleTitle=艾伯维丙肝鸡尾酒Viekira Pak治疗肝硬化1b型丙肝实现100%治愈率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b72b52528ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350199, encodeId=c63d135019963, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维治疗白血病新药venetoclax获FDA突破性药物认证, objectType=article, longId=50557, objectId=7edd5055e70, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7edd5055e70, replyNumber=0, likeNumber=88, createdTime=2015-05-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7edd5055e70, moduleTitle=艾伯维治疗白血病新药venetoclax获FDA突破性药物认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7edd5055e70)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350198, encodeId=6bc71350198da, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维新药Duopa改善帕金森症患者病情, objectType=article, longId=50309, objectId=012b503097f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=012b503097f, replyNumber=0, likeNumber=86, createdTime=2015-05-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=012b503097f, moduleTitle=艾伯维新药Duopa改善帕金森症患者病情, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=012b503097f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1350197, encodeId=e49c135019ed2, content=<a href='/topic/show?id=bc1086e4652' target=_blank style='color:#2F92EE;'>#艾伯维#</a>, objectTitle=艾伯维丙肝新药Viekira + Exviera获欧洲药品委员会批准, objectType=article, longId=45691, objectId=02a245691ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02a245691ef, replyNumber=0, likeNumber=82, createdTime=2015-01-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02a245691ef, moduleTitle=艾伯维丙肝新药Viekira + Exviera获欧洲药品委员会批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02a245691ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

艾伯维

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维关节炎新药upadacitinib抵达3期终点效果优于Humira

2018-04-12

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维旗下维建乐®（奥比帕利片）联合易奇瑞®（达塞布韦钠片）治疗方案在华获批用于治疗基因1型慢性丙肝

2017-12-08

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维修订增强型拟肽类PIs口服联合制剂克力芝®（洛匹那韦/利托那韦）的说明书

2017-11-25

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维产品修美乐在华获批用于治疗中重度斑块型银屑病

2017-06-09

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功

2017-01-11

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

ASRM2016：女性福音！艾伯维妇科药物Elagolix治疗子宫内膜异位症显著减少经期和非经期盆腔疼痛

2016-10-24

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

ECTRIMS 2016：百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta疗效显著优于Avonex（干扰素β-1a）

2016-09-26

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

喜讯！百健和艾伯维每月一次皮下注射多发性硬化症药物Zinbryta获欧盟批准

2016-07-09

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）

2016-06-07

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

喜讯！FDA批准百健/艾伯维每月一次皮下注射多发性硬化症药物Zinbryta

2016-06-01

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维旗舰产品修美乐（Humira）获欧盟CHMP支持批准，治疗非感染性葡萄膜炎

2016-05-30

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

6个适应症！FDA批准艾伯维突破性药物Imbruvica治疗小淋巴细胞性淋巴瘤（SLL）

2016-05-12

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维/罗氏白血病新药 Venclexta再获FDA突破性药物资格

2016-04-18

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

5个适应证！FDA批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）

2016-03-13

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

性福音！艾伯维妇科药物Elagolix治疗子宫内膜异位症III期项目大获成功

2016-02-21

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维白血病新药venetoclax斩获FDA第2个突破性药物资格

2016-01-26

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维丙肝鸡尾酒Viekira Pak治疗肝硬化1b型丙肝实现100%治愈率

2015-06-28

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维治疗白血病新药venetoclax获FDA突破性药物认证

2015-05-13

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维新药Duopa改善帕金森症患者病情

2015-05-08

zhaojie88 (审核中...)

前往app查看评论内容

#艾伯维#

艾伯维丙肝新药Viekira + Exviera获欧洲药品委员会批准

2015-01-21

科室
- - 订阅+
  - 更多科室
工具
服务